Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2002

View Archived Issues

Strong immune response and good tolerability for Innogenetics' E1 vaccine for hepatitis C

Medtronic to acquire VidaMed

Interference with viral mRNA nuclear export as an anti-HIV strategy

New oral streptogramin further characterized at ICAAC meeting

Genelabs presents research on DNA-targeting antifungal compounds

New family of DNA-targeting antibacterial small molecules designed at Genelabs

Evidence that AGEs represent a treatment target for diabetic complications

MetaPhore's SOD mimetic M-40403 used successfully against experimental colitis in rats

Azasordarins show promise in preclinical testing as antifungal agents

ABX-EGF enters phase II trial for colorectal cancer

ImClone's BLA filing for Erbitux not accepted by FDA

Patient enrollment completed in trials for MedImmune humanized monoclonal antibodies

Novel Roche compounds for type 2 diabetes

Solid-phase synthesis and selection of dual PPARgamma/PPARdelta agonist

Cephalon completes acquisition of Lafon

Sterol derivatives claimed as antiproliferative and antiangiogenic agents

Recent patent discloses cyclic amidine compounds for improving cognitive function

FDA issues approvable letter for Trileptal as monotherapy for epilepsy in children

Naturally produced PTP inhibitors in the Takeda pipeline

5-HT2C agonists with a furoindazole structure claimed by Yamanouchi

Japanese researchers identify new steroid sulfatase inhibitors

Combination treatment for nonbacterial prostatitis under clinical study at NIH

Discovery of gene mutation that causes increased bone mass may lead to osteoporosis treatment

NIAID and Merck & Co. collaborate to further HIV vaccine development

4SC identifies drug candidates for treatment of diseases caused by bacterial biofilms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...